• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Accelovance, FHI 360 ink agreement

Accelovance, FHI 360 ink agreement

November 5, 2015
CenterWatch Staff

Accelovance, a Rockville, Md.-based global CRO focusing in oncology, vaccines, and general medicine, and FHI 360, a Durham, N.C.-based global nonprofit organization with CRO capabilities focusing on clinical research in developing countries, have entered into a strategic alliance to more comprehensively serve the international drug development research efforts of pharmaceutical, governmental and nonprofit organizations.

The strategic alliance expands Accelovance's service offering and capabilities in developing countries in Africa, Asia Pacific and South America, and expands FHI's capabilities and coverage in North America and Europe.

FHI 360 Director of Global Research & Services Ted Fitzgerald said, “This opportunity enables both organizations to maximize geographic coverage to deliver cross functional support anywhere in the world to meet the research needs of drug development sponsors. For FHI 360, leveraging Accelovance’s clinical development expertise and resources in the U.S. and Europe is a natural progression in our strong relationship.”

Both CROs have been collaborating on projects in several regions of the world, most notably on a large phase III Ebola vaccine trial in Sierra Leone. The strategic alliance enables both companies to expand their global footprint and support the full program drug development needs of pharmaceutical, governmental, and nonprofit organizations.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing